Ovid Therapeutics
OVID
67 hedge funds and large institutions have $109M invested in Ovid Therapeutics in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 22 reducing their positions, and 16 closing their positions.
0.51% more ownership
Funds ownership: 49.45% → 49.96% (+0.51%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less capital invested
Capital invested by funds: $113M → $109M (-$3.68M)
7% less funds holding
Funds holding: 72 → 67 (-5)
31% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 16
32% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.58M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$1.05M |
| 3 |
CA
CHI Advisors
New York
|
+$570K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$469K |
| 5 |
Bank of New York Mellon
New York
|
+$461K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.37M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.12M |
| 3 |
E
Ergoteles
New York
|
-$560K |
| 4 |
HF
HRT Financial
New York
|
-$384K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$274K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Principal Financial Group
Des Moines,
Iowa
| – | -$42K | -12,598 | Closed |
|
|
SSA
77
Schonfeld Strategic Advisors
New York
| – | -$34K | -10,100 | Closed |
|
78
Barclays
London,
United Kingdom
| – | -$28K | -8,218 | Closed |
|
|
AFS
79
Annapolis Financial Services
Annapolis,
Maryland
| – | -$17K | -5,000 | Closed |
|
|
OSAM
80
O'Shaughnessy Asset Management
Stamford,
Connecticut
| – | -$6K | -1,913 | Closed |
|
|
PCM
81
Penserra Capital Management
Orinda,
California
| – | -$5K | -1,555 | Closed |
|
OVID Hedge Fund Activity: Q4 2021 in Review
67 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q4 2021, worth a combined $109M — down 3.3% from $113M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of OVID and 11 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 15 added.
The largest buyer was Stonepine Capital Management, adding an estimated $2.58M. The largest seller was Ikarian Capital, cutting an estimated $1.37M.
- 67 institutional investors held Ovid Therapeutics (OVID) as of Q4 2021, down from 72 in Q3 2021.
- Funds reported $109M of Ovid Therapeutics stock for Q4 2021, down 3.3% quarter-over-quarter.
- 11 funds opened new Ovid Therapeutics positions in Q4 2021 and 16 closed out, a net change of -5 holders.
- The largest Ovid Therapeutics buyer in Q4 2021 was Stonepine Capital Management, an estimated $2.58M added.
- The largest Ovid Therapeutics seller in Q4 2021 was Ikarian Capital, an estimated $1.37M sold.
Based on aggregated 13F filings for Q4 2021.